Allergic rhinitis

Nature Reviews Disease Primers, Journal Year: 2020, Volume and Issue: 6(1)

Published: Dec. 3, 2020

Allergic rhinitis (AR) is caused by immunoglobulin E (IgE)-mediated reactions to inhaled allergens and one of the most common chronic conditions globally. AR often co-occurs with asthma conjunctivitis a global health problem causing major burden disability worldwide. Risk factors include inhalant occupational allergens, as well genetic factors. impairs quality life, affects social school work, associated substantial economic costs. The Rhinitis its Impact on Asthma (ARIA) initiative classified into intermittent or persistent mild moderate/severe. diagnosis based clinical history and, if needed in patients uncontrolled despite medications long-lasting symptoms, skin tests presence serum-specific IgE antibodies allergens. frequently used pharmacological treatments oral, intranasal ocular H1-antihistamines, corticosteroids fixed combination H1-antihistamines corticosteroids. Allergen immunotherapy prescribed specialist using high-quality extracts stratified effective symptoms. Real-world data obtained mobile technology offer new insights phenotypes management. outlook for includes better understanding novel multimorbid phenotypes, assessment patient-centred shared decision-making. This Primer Bousquet colleagues summarizes epidemiology, mechanisms, treatment allergic rhinitis. In addition, it reviews quality-of-life issues faced provides an overview how technologies could improve patient care.

Language: Английский

---

Mast Cell Biology at Molecular Level: a Comprehensive Review

Clinical Reviews in Allergy & Immunology, Journal Year: 2019, Volume and Issue: 58(3), P. 342 - 365

Published: Dec. 12, 2019

Language: Английский

---

Allergen Immunotherapy in Children User’s Guide

Pediatric Allergy and Immunology, Journal Year: 2020, Volume and Issue: 31(S25), P. 1 - 101

Published: May 1, 2020

Abstract Allergen immunotherapy is a cornerstone in the treatment of allergic children. The clinical efficiency relies on well‐defined immunologic mechanism promoting regulatory T cells and downplaying immune response induced by allergens. Clinical indications have been well documented for respiratory allergy presence rhinitis and/or asthma, to pollens dust mites. Patients who had an anaphylactic reaction hymenoptera venom are also good candidates allergen immunotherapy. Administration currently mostly either subcutaneous injections or sublingual administration. Both methods extensively studied pros cons. Specifically children, choice method administration according patient's profile important. Although widely used, there need improvement. More particularly, biomarkers prediction success treatments needed. strength may be boosted use better adjuvants. Finally, novel formulations might more efficient improve adherence treatment. This user's guide reviews current knowledge aims provide guidance healthcare professionals taking care children undergoing

Language: Английский

---

Allergen immunotherapy: past, present and future

Nature reviews. Immunology, Journal Year: 2022, Volume and Issue: 23(5), P. 317 - 328

Published: Oct. 17, 2022

Language: Английский

---

Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response

Immunity, Journal Year: 2021, Volume and Issue: 54(2), P. 291 - 307.e7

Published: Jan. 15, 2021

Language: Английский

---

Functions and regulation of T cell-derived interleukin-10

Seminars in Immunology, Journal Year: 2019, Volume and Issue: 44, P. 101344 - 101344

Published: Aug. 1, 2019

Language: Английский

---

Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE– and Institute of Medicine–based recommendations

Annals of Allergy Asthma & Immunology, Journal Year: 2023, Volume and Issue: 132(3), P. 274 - 312

Published: Dec. 18, 2023

Language: Английский

---

Diverse immune mechanisms of allergen immunotherapy for allergic rhinitis with and without asthma

Journal of Allergy and Clinical Immunology, Journal Year: 2022, Volume and Issue: 149(3), P. 791 - 801

Published: Jan. 29, 2022

Allergen immunotherapy (AIT) is an effective treatment for allergic rhinitis, inducing long-term clinical tolerance to the sensitizing allergen. Clinical induction can be achieved when AIT administered at least 3 years. associated with modulation of innate and adaptive immune systems. This comprises inhibition IgE-dependent activation mast cells basophils in local target organ, suppression TH2 cells, deviation toward TH1 T B regulatory production allergen-neutralizing antibodies. However, recent developments their underpinning mechanisms have revealed that AIT, subcutaneously or sublingually, induces regulation through novel cell targets molecular mechanisms. comprehensive review discusses how driven by subcutaneous sublingual a subset lymphoid proinflammatory TH2, allergen-specific (TH2A), follicular helper cells. Moreover, they are exhaustion TH2A differential expression nasal systemic IgA Uncovering successful will allow development targeted therapeutics rhinitis without asthma.

Language: Английский

---

Disease-modifying anti-asthmatic drugs

The Lancet, Journal Year: 2022, Volume and Issue: 399(10335), P. 1664 - 1668

Published: April 1, 2022

Language: Английский

---

Guideline on allergen immunotherapy in IgE-mediated allergic diseases

Allergologie select, Journal Year: 2022, Volume and Issue: 6(01), P. 167 - 232

Published: Jan. 1, 2022

Not available.

Language: Английский

---